全文获取类型
收费全文 | 185768篇 |
免费 | 13474篇 |
国内免费 | 535篇 |
专业分类
耳鼻咽喉 | 1978篇 |
儿科学 | 4791篇 |
妇产科学 | 4085篇 |
基础医学 | 28016篇 |
口腔科学 | 5041篇 |
临床医学 | 17024篇 |
内科学 | 38456篇 |
皮肤病学 | 3162篇 |
神经病学 | 18132篇 |
特种医学 | 7268篇 |
外国民族医学 | 9篇 |
外科学 | 23532篇 |
综合类 | 1023篇 |
现状与发展 | 1篇 |
一般理论 | 178篇 |
预防医学 | 18842篇 |
眼科学 | 3444篇 |
药学 | 11471篇 |
1篇 | |
中国医学 | 316篇 |
肿瘤学 | 13007篇 |
出版年
2023年 | 826篇 |
2022年 | 662篇 |
2021年 | 2986篇 |
2020年 | 2254篇 |
2019年 | 3204篇 |
2018年 | 3997篇 |
2017年 | 3397篇 |
2016年 | 3798篇 |
2015年 | 4167篇 |
2014年 | 5667篇 |
2013年 | 7678篇 |
2012年 | 11696篇 |
2011年 | 12025篇 |
2010年 | 6554篇 |
2009年 | 6500篇 |
2008年 | 10466篇 |
2007年 | 11015篇 |
2006年 | 10281篇 |
2005年 | 10080篇 |
2004年 | 8855篇 |
2003年 | 8385篇 |
2002年 | 7700篇 |
2001年 | 5043篇 |
2000年 | 4923篇 |
1999年 | 4518篇 |
1998年 | 2010篇 |
1997年 | 1693篇 |
1996年 | 1702篇 |
1995年 | 1578篇 |
1994年 | 1434篇 |
1993年 | 1340篇 |
1992年 | 3075篇 |
1991年 | 2763篇 |
1990年 | 2635篇 |
1989年 | 2445篇 |
1988年 | 2256篇 |
1987年 | 1987篇 |
1986年 | 1910篇 |
1985年 | 1884篇 |
1984年 | 1429篇 |
1983年 | 1265篇 |
1982年 | 840篇 |
1981年 | 763篇 |
1980年 | 667篇 |
1979年 | 1080篇 |
1978年 | 738篇 |
1977年 | 647篇 |
1975年 | 553篇 |
1974年 | 593篇 |
1973年 | 586篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
We describe a 3‐month‐old child with an infantile hemangioma on the forehead with a blanched macule provoked by topical treatment with propranolol. This observation demonstrates that topically applied (non‐selective) beta‐blockers may induce blanched macules at the site of application, a side effect due to peripheral vasoconstriction of blood vessels by non‐selective beta‐2 blockade. This side effect was linked due to overuse and was reversible. This case illustrates the importance of providing thorough instructions regarding topical propranolol application. 相似文献
22.
23.
Erik de Bakker Mirthe A. M. van der Putten Martijn W. Heymans Sander W. Spiekstra Taco Waaijman Liselotte Butzelaar Vera L. Negenborn Vivian K. Beekman Erman O. Akpinar Thomas Rustemeyer Frank B. Niessen Susan Gibbs 《Experimental dermatology》2021,30(1):169-178
Unpredictable hypertrophic scarring (HS) occurs after approximately 35% of all surgical procedures and causes significant physical and psychological complaints. Parallel to the need to understanding the mechanisms underlying HS formation, a prognostic tool is needed. The objective was to determine whether (systemic) immunological differences exist between patients who develop HS and those who develop normotrophic scars (NS) and to assess whether those differences can be used to identify patients prone to developing HS. A prospective cohort study with NS and HS groups in which (a) cytokine release by peripheral blood mononuclear cells (PBMC) and (b) the irritation threshold (IT) after an irritant (sodium lauryl sulphate) patch test was evaluated. Univariate regression analysis of PBMC cytokine secretion showed that low MCP‐1, IL‐8, IL‐18 and IL‐23 levels have a strong correlation with HS (P < .010‐0.004; AUC = 0.790‐0.883). Notably, combinations of two or three cytokines (TNF‐a, MCP‐1 and IL‐23; AUC: 0.942, Nagelkerke R2: 0.727) showed an improved AUC indicating a better correlation with HS than single cytokine analysis. These combination models produce good prognostic results over a broad probability range (sensitivity: 93.8%, specificity 86.7%, accuracy 90,25% between probability 0.3 and 0.7). Furthermore, the HS group had a lower IT than the NS group and an accuracy of 68%. In conclusion, very fundamental immunological differences exist between individuals who develop HS and those who do not, whereas the cytokine assay forms the basis of a predictive prognostic test for HS formation, the less invasive, easily performed irritant skin patch test is more accessible for daily practice. 相似文献
24.
25.
26.
27.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
28.
Quality of Life Research - To determine the predictive value of quality of life for mortality at the domain and item levels. This longitudinal study was carried out in a sample of 479 Dutch people... 相似文献
29.
30.
Die Anaesthesiologie - Simulationstraining ist für die Notfallmedizin unverzichtbar, insbesondere in Hinsicht auf eine verbesserte Patientensicherheit. Methoden und Technologien umfassen ein... 相似文献